RemeGen readies $514M IPO as HKEX adds jewel to the crown

Nasdaq may boast of a biotech boom with the sheer number of companies in its IPO queue. But when it comes to chart-topping hauls, HKEX apparently takes the crown.

The latest record setter is RemeGen, a Yantai, Shandong-based biotech that — months after drawing in a stellar slate of crossover investors for a $100 million-plus round — is set to raise up to $514 million from its public debut in Hong Kong.